Abstract
To grow and metastasize, solid tumours must develop their own blood supply by neo-angiogenesis. Thalidomide inhibits the processing of mRNA encoding peptide molecules including tumour necrosis factor-alpha (TNF-α) and the angiogenic factor vascular endothelial growth factor (VEGF). This study investigated the use of continuous low dose Thalidomide in patients with a variety of advanced malignancies. Sixty-six patients (37 women and 29 men; median age, 48 years; range 33–62 years) with advanced measurable cancer (19 ovarian, 18 renal, 17 melanoma, 12 breast cancer) received Thalidomide 100 mg orally every night until disease progression or unacceptable toxicity was encountered. Three of 18 patients with renal cancer showed partial responses and a further three patients experienced stabilization of their disease for up to 6 months. Although no objective responses were seen in the other tumour types, there were significant improvements in patients’ sleeping (P< 0.05) and maintained appetite (P< 0.05). Serum and urine concentrations of basic fibroblast growth factor (bFGF), TNF-α and VEGF were measured during treatment and higher levels were associated with progressive disease. Thalidomide was well tolerated: Two patients developed WHO Grade 2 peripheral neuropathy and eight patients developed WHO grade 2 lethargy. No patients developed WHO grade 3 or 4 toxicity. Further studies evaluating the use of Thalidomide at higher doses as a single agent for advanced renal cancer and in combination with biochemotherapy regimens are warranted. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Asscher W (1994) Safety of Thalidomide. Br Med J 309: 193–194 (letter)
Battegay EJ (1995) Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73: 333–346
Boshoff C and Jones AL (1996) Tumour necrosis factor. Immunotherapy in Cancer, Gore ME, Riches P (eds), pp. 77–103, John Wiley: London
Burrows FJ and Thorpe PE (1994) Vascular targeting – a new approach to the therapy of solid tumours. Pharmacol Ther 64: 155–174
Bussolino F, Albini A, Camussi G, Presta M, Vigliotto G, Ziche M and Persico G (1996) Role of soluble mediators in angiogenesis. Eur J Cancer 32A: 2401–2412
Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR and Baguley BC (1995) Effect of Thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxantheone-4-acetic acid. Br J Cancer 72: 339–343
Crawford CL (1994) Use of Thalidomide in leprosy. Adverse Drug React Toxicol Rev 13: 177–192
D’Amato RJ, Loughnan MS, Flynn E and Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082–4085
Eisenbud L, Horowitz I and Kay B (1987) Recurrent aphthous stomatitis of the Behçet’s type: successful treatment with Thalidomide. Oral Surg Oral Med Oral Pathol 64: 289–292
Erhard H, Rietveld FJ, van Altena MC, Brocker EB, Ruiter DJ and de Waal RM (1997) Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res 2: S19–26
Fajardo LF, Kwan HH, Kowalski J, Prionas SD and Allison AC (1992) Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol 140: 539–544
Folkman J (1995 a) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27–31
Folkman J (1995 b) Clinical applications of research on angiogenesis. N Engl J Med 333: 1757–1763
Fullerton PM and Kremer M (1961) Neuropathy after intake of Thalidomide (Distaval). Br Med J 2: 853–858
Gasparini G (1996) Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Eur J Cancer 32A: 2485–2493
Hamada J, Cavanaugh PG, Lotan O and Nicolson GL (1992) Separable growth and migration factors for large cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer 66: 349–354
Haslett PA (1998) Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 25: 53–57
Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamuru T, Brem H and Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555–557
Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff M, Wu AW, MacPhail LA, Vasquez GJ and Wohl DA (1997) Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 336: 1487–1493
Koo AS, Armstrong C, Bochner B, Shimabukuro T, Tso CL, de Kernion JB and Belldegrum A (1992) Interleukin-6 and renal cell cancer: production, regulation and growth effects. Cancer Immunol Immunother 35: 97–105
Lenz W (1962) Thalidomide and congenital abnormalities. Lancet 1: 45 (letter)
Lopez-Hanninen E, Kirchner H and Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155: 19–25
McBride WG (1961) Thalidomide and congenital abnormalities. Lancet 2: 1358 (letter)
Millar AB, Hoogstraten B and Staquet M (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Mizutani Y, Bonavida B, Nio Y and Yoshida O (1994) Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha downregulation in tumor cell sensitization. J Urol 151: 1697–1702
Parman T, Wiley MJ and Wells PG (1999) Free radical-mediated oxidative DNA damage in the mechanism of Thalidomide teratogenicity. Nat Med 5: 582–585
Powell RJ and Gardner-Medwin JM (1994) Guideline for the clinical use and dispensing of Thalidomide. Postgrad Med J 70: 901–904
Schiffenbauer YS, Abramovitch R, Meir G, Nevo N, Holzinger M, Itin A, Keshet E and Neeman M (1997) Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci USA 94: 13203–13208
Talbot DC and Brown PD (1996) Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32A: 2528–2533
Tramontana JM, Utaipat U, Molloy A, Akarasewi P, Burroughs M, Makonkawkeyoon S, Johnson B, Klausner JD, Rom W and Kaplam G (1995) Thalidomide treatment reduces tumour necrosis alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1: 384–397
Voest EE, Kenyon BM, O’Reilly MS, Truitt G, D’Amato RJ and Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87: 581–586
Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM and Wingard JR (1992) Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326: 1055–1058
Weidmann E, Bergmann L, Stock J, Kirsten R and Mitrou PS (1992) Rapid cytokine release in cancer patients treated with interleukin-2. J Immunother 12: 123–131
Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9–19
Weidner N, Semple JP, Welch WR and Folkman J (1991) Tumor angiogenesis and metastasis – correlation in invasive breast cancer. N Engl J Med 324: 1–8
Wettstein AR and Meagher AP (1997) Thalidomide in Crohn’s disease. Lancet 350: 1445–1446 (letter)
Yoneda T, Alsina MA, Chavez JB, Bonewald L, Nishimura R and Mundy GR (1991) Evidence that tumour necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcaemia, and leukocytosis in a human tumour in nude mice. J Clin Invest 87: 977–985
Ziegler J (1996) Angiogenesis research enjoys growth spurt in the 1990s. J Natl Cancer Inst 88: 786–788
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Eisen, T., Boshoff, C., Mak, I. et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82, 812–817 (2000). https://doi.org/10.1054/bjoc.1999.1004
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.1999.1004
Keywords
This article is cited by
-
The efficacy and safety of thalidomide for treating metastatic breast cancer: a systematic review
Oncology and Translational Medicine (2020)
-
Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment
Medical Oncology (2018)
-
Scalable and green process for the synthesis of anticancer drug lenalidomide
Chemistry of Heterocyclic Compounds (2015)
-
Metronomic chemotherapy for cancer treatment: a decade of clinical studies
Cancer Chemotherapy and Pharmacology (2013)
-
Phase I trial of metronomic oral vinorelbine in patients with advanced cancer
Cancer Chemotherapy and Pharmacology (2011)
